MATD3: quote, dividends and indicators for Rede Mater Dei de Saúde

Rede Mater Dei de Saúde, traded on B3 under the ticker MATD3, traces its origins to 1973, when it was founded by physician José Salvador Silva in Belo Horizonte. The first hospital unit, Hospital Mater Dei Santo Agostinho, was inaugurated in 1980 and became the company’s expansion base. Over the following decades, the company built a track record of pioneering initiatives in several areas of healthcare in Minas Gerais, such as creating the state’s first Pediatric Intensive Care Unit in 1986 and developing the mastology area through Unimater, which positioned it as a reference center in the diagnosis and treatment of breast cancer. Also in the 1980s, the hospital performed one of the first successful in vitro fertilization procedures in Brazil, reinforcing its role in assisted reproduction. From the 1990s onward, Rede Mater Dei began investing heavily in professionalizing management, joining management excellence programs such as PAEX and bringing the medical staff closer to strategic decision-making.

Rede Mater Dei de Saúde’s business model is based on the integrated operation of hospitals, outpatient clinics, and clinical laboratories, with an exclusive focus on hospital services. The company operates as a full-service healthcare platform, offering clinical and surgical inpatient care, adult and pediatric intensive therapies, emergency care, oncology, diagnostic medicine, and high-complexity services, including robotic surgery and bone marrow transplantation. Service integration makes it possible to capture revenue from different links in the healthcare chain within the same physical infrastructure, which supports economies of scale, protocol standardization, and operational efficiency. The company concentrates its revenue in hospital services, measured net of the usual sector deductions, such as taxes, discounts, and denials arising from its relationship with health plan operators.

From an operational standpoint, Rede Mater Dei de Saúde organizes its activities around a single accounting segment, hospitals, but internally structures its offerings by service lines. For inpatient and intensive care units, it operates multidisciplinary teams involving physicians, nurses, physical therapists, psychologists, speech therapists, and other professionals. The company maintains surgical centers capable of handling low, medium, and high-complexity procedures, including robotic surgery technology such as the Da Vinci Xi system in multiple units and around five rooms dedicated to this type of procedure. The network also operates 24-hour emergency rooms in several specialties, as well as the Mater Dei Urgente ambulance service, equipped for emergency care with mobile ICU support. In oncology, a highlight is the Integrated Cancer Hospital, designed specifically for cancer care and offering clinical oncology, onco-hematology, pediatric oncology, oncogenetics, cardio-oncology, oncofertility, and a bone marrow transplant unit, in addition to chemotherapy bays distributed across the group’s units.

Rede Mater Dei’s geographic footprint expanded gradually from Belo Horizonte, where it consolidated its presence with the Santo Agostinho unit, the opening of Mater Dei Contorno in 2014, and the inauguration of the hospital in the Betim-Contagem region in 2019, reinforcing its position as one of the largest private healthcare networks in Minas Gerais in terms of bed count. The company then began a national expansion, establishing operations in Bahia, Goiás, and Pará. Currently, Rede Mater Dei de Saúde has approximately nine hospital units and about 2,200 built beds, of which around 1,200 are operational, distributed across regions such as the Belo Horizonte metropolitan area, Salvador, Uberlândia, Goiânia, and Feira de Santana. This capillarity aims to combine a presence in major urban centers and relevant regional hubs, while maintaining a focus on serving middle- and high-income segments in a hospital market considered fragmented.

In its commercial relationships, Rede Mater Dei de Saúde maintains contracts with various health plan operators, insurers, and self-managed plans, including groups such as Allianz, Amil, Bradesco Saúde, Caixa Econômica Federal (health), Cassi, SulAmérica, pension funds, and corporate plans of large companies. Revenue is notably concentrated, with at least one client accounting for more than 10% of net operating revenue in 2025. This structure reflects the nature of the supplementary healthcare sector in Brazil, in which hospital providers depend on negotiations over price adjustments, contractual conditions, and care volumes with regulated operators. The company targets its services primarily at the supplementary health segment, both corporate plans and individual and group plans, while also serving occasional demand from other payers, maintaining a diversified client base but with some operators representing a larger share of revenue.

Rede Mater Dei de Saúde’s technology platform is a central element of its value proposition. The company operates a broad set of diagnostic medicine equipment, including CT scanners, MRI machines, PET-CT, X-ray, mammography, bone densitometry, hemodialysis bays, and equipment dedicated to bone marrow transplants. Diagnostic medicine is integrated into the hospital structure, allowing imaging exams and lab tests to be conducted in inpatient or outpatient settings, with a focus on safety, fast turnaround, and monitoring of adverse reactions. The Human Reproduction Center, located at the Santo Agostinho unit, offers assisted reproduction techniques with a lab integrated into the surgical structure. In addition, the Mais Saúde Mater Dei outpatient clinic in Belo Horizonte was designed for the longitudinal follow-up of chronic patients and specific clinical cases, with its own scheduling and integration with diagnostic services.

On the regulatory front, Rede Mater Dei de Saúde’s activities are mainly influenced by the National Supplementary Health Agency (ANS) and the National Health Surveillance Agency (Anvisa). Its relationship with health plan operators is subject to ANS rules on contracts between providers and operators, criteria for price adjustments, coverage standards, replacement of providers in accredited networks, and hospital network rules. Recent regulatory resolutions define requirements for formalizing contracts, adjustment indices in specific situations, and conditions for the replacement or resizing of provider networks. In parallel, the operation of hospitals, laboratories, and diagnostic services depends on health licenses issued by federal, state, and municipal authorities under Anvisa’s coordination. This includes controls over waste disposal, the use of radioactive materials, medicines, and chemical products, as well as compliance of physical facilities and care processes with health and safety standards set out in specific regulations.

In the environmental, social, and governance (ESG) arena, Rede Mater Dei de Saúde has structured its management with a strong component of integrated clinical and corporate governance. The model adopts standardized protocols, care quality indicators monitored on dashboards, and systematic use of the PDCA continuous improvement methodology to review processes and outcomes. The company was one of the first in the country to obtain major quality accreditations such as ONA Level 3, NIAHO, and Joint Commission International, in addition to ISO certifications, signaling alignment with international standards of patient safety and hospital management. On the social and human capital front, it maintains training and development programs such as the Institutional Training Center, the Lidera Mais leadership development program, and medical and nursing residency programs in several specialties. In governance, the company has set up a board of directors, a family succession plan, and practices aligned with B3’s Novo Mercado, while also using digital platforms such as the client portal and the Meu Mater Dei app to enhance transparency, access to care information, and care integration.